Orchestra BioMed Holdings (OBIO) Common Equity (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Common Equity for 7 consecutive years, with $41.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 144.36% year-over-year to $41.2 million; the TTM figure through Mar 2026 stood at $41.2 million (up 144.36% YoY), while the FY2025 annual figure was $53.6 million, up 62.54% from the prior year.
• Common Equity retreated to $41.2 million in Q1 2026 per OBIO's latest filing, from $53.6 million in the prior quarter.
• Across five years, Common Equity topped out at $99.8 million in Q1 2023 and bottomed at $78000.0 in Q1 2022.
• Historically, Common Equity has averaged $50.4 million across 5 years, with a median of $52.5 million in 2022.
• Annual changes were most pronounced in 2023 — Common Equity soared 127787.18% — and 2025, when it plunged 99.33%.
• Orchestra BioMed Holdings' Common Equity stood at $52.5 million in 2022, then rose by 29.52% to $68.0 million in 2023, then plunged by 51.56% to $33.0 million in 2024, then jumped by 62.54% to $53.6 million in 2025, then slipped by 23.11% to $41.2 million in 2026.
• Business Quant data shows OBIO's Common Equity at $41.2 million in Q1 2026, $53.6 million in Q4 2025, and $43.7 million in Q3 2025.